Mucopolysaccharidosis type I-Hurler (MPS1-H) is the most severe form of inherited metabolic diseases caused by mutations in the IDUA gene. The resulting deficiency of alpha L-iduronidase enzyme leads to a progressive accumulation of glycosaminoglycans in lysosomes which damages multiple organs and highly reduces life expectancy of affected children. Skin fibroblasts of a 2-year-old MPS1-H male, carrying two mutations in each IDUA alleles (H358_T364del; W402X), were reprogrammed into induced pluripotent stem cells (iPSCs) using the CytoTune-iPS Sendai Reprogramming method applying Yamanaka-factors (OCT4, SOX2, KLF4, c-MYC). iPSCs expressed pluripotency transcription factors while iPSC-derived embryoid bodies reveal markers of the three germ layers.
Resource details
Mucopolysaccharidosis type I-Hurler (MPS1-H), the most severe form of MPSs, is a rare lysosomal storage disorder caused by the deficiency of alpha L-iduronidase (IDUA), which is the needed enzyme to catabolize glycosaminoglycans (GAGs) (Giugliani et al., 2010) . Impairment of its activity leads to progressive accumulation of GAGs followed by dysfunction of many biological systems and organs, such as affections of cardiovascular, respiratory and central nervous system. Without enzyme replacement therapy or hematopoietic stem cell transplantation, this autosomal recessive disorder is fatal in early childhood (before 5 years old) (Tolar et al., 2008) .
Skin fibroblasts were isolated from skin tissues of a 2-year-old male, MPS1-H diagnosed by Division of Metabolism and Children's Research Center of University Children's Hospital of Zürich (Switzerland). Lossof-function of alpha L-iduronidase and resulting MPS1-H symptoms have genetically been associated to the presence of two distinct mutations distributed on the two alleles of the IDUA gene (NM_000203.5(IDUA):c.1073_1093del (p.His358_Thr364del) and NM_000203.4(IDUA):c.1205 G>A (p.Trp402Ter)) (Table 1, Fig. 1A ).
MPS1 fibroblasts have been reprogrammed into MPS1 iPSC line by using integration-free CytoTune-iPS Sendai Reprogramming system, using the Yamanaka factors (OCT4, SOX2, KLF4, and c-MYC) (Takahashi et al., 2007) . After few passages, newly generated MPS1-H.2y.S4 iPSC were fully characterized. First, the genetic identity of isolated iPSC and the parental MPS1 patient fibroblasts have been confirmed by STR analysis (Table 1) . Both IDUA mutations, identified in fibroblasts, were also detected in resulting iPSC ( Fig. 1A) . At passage 12, normal karyotype and genome integrity were assessed by Comparative Genomic Hybridization (CGH) array. While this technique cannot identify balanced translocations, cells present a normal karyotype without genomic imbalances ( Fig. 1B) . Performance of a PCR-based Mycoplasma test certified our cell culture as mycoplasma-free ( Fig. S1 ).
Based on the clear borders of colonies that are composed of small, tightly packed cells with large nucleoli, these cells display morphological features and organization of pluripotent stem cells (Fig. 1C ).
Although alkaline phosphatase activity was detected in the colonies (Fig. 1D ), validation of the reprogramming of fibroblasts into bona fide iPSC was also confirmed by the expression of pluripotency transcription factors by flow cytometric analysis ( Fig. 1E ) and immunofluorescence staining ( Fig. 1F ). Indeed, more than 94% of cells were positive for NANOG, OCT4 and SOX2 by FACS analysis.
In order to further confirm their pluripotency, embryoid bodies (EBs) have been generated from the cells ( Fig. 1H ) and were spontaneously differentiated in vitro for 24 days. Differentiation potential of the cells was validated by the expression of specific markers of the three germ layers, both by immunofluorescence staining (Fig. 1I ) and PCR ( Fig. 1 ). Expression of SOX17 and AFP revealed a differentiation toward the endoderm, while ACTA2 and FOXA2 highlighted a mesodermal pattern and finally TUBB3 and MAP1B the presence of ectoderm germ layer.
In conclusion, our newly reprogrammed MPS1-H.2y.S4 iPSC presents all features of pluripotent stem cells and is ready to be used for MPS1-H modelling or for drug discovery studies.
Materials and methods

Human dermal fibroblast reprogramming
Fibroblasts, isolated from the skin biopsy of a 2-year-old male MPS1 patient, were expanded in fibroblast medium (DMEM, 10% fetal bovine serum (FBS), 1% Non-Essential amino acids (NEAA), 1% Sodium pyruvate, 1% Glutamine and 1% Pen/Strep). An amount of 2 × 10 5 MPS1 fibroblasts were plated on 6-well plate and transduced with the Yamanaka factors (OCT3/4, NANOG, KLF4, c-MYC), using CytoTune®-iPS Sendai Reprogramming Kit (Thermo Fisher Scientific) at an MOI of 5:5:3. Cells were maintained in fibroblast medium until D4, when medium was switched to mTeSR™1 medium (StemCell Technologies). Colonies were picked manually between D19 and D24 on Matrigel®coated culture dishes and were routinely passaged every 5-6 days, at a split ratio of 1:5, using 0.5 mM EDTA (Sigma-Aldrich). All cells were cultured at 37°C in humidified atmosphere containing 5% CO 2 . 
Pluripotency flow cytometric assay
Expression of pluripotent stem cell transcription factors of MPS1-H.2y.S4 iPSC was validated by flow cytometry, using BD Stemflow Human Pluripotent Stem Cell Transcription Factor Analysis Kit® (BD Biosciences) according to the manufacturer's instructions. Acquisition was performed using ACCURI 6 flow cytometer. Data analysis was carried out with BD Accuri C6 software.
Alkaline phosphatase staining
iPSC colonies were fixed with 4% paraformaldehyde (PFA) for 10 min at room temperature (RT), then incubated with NBT solution (Sigma-Aldrich) for 30 min at RT. Stained colonies were observed under Eclipse Ts2 inverted microscope (Nikon). Scale bar = 50 µm.
Embryoid bodies assay
The iPSC clones were spontaneously differentiated into the three embryonic germ layers. Colonies were dissociated with Accutase® for 5 min at 37°C and uniform EBs were formed by plating 1000 cells/ microwell of AggreWell™ plates, in mTeSR™1 medium supplemented with 10 µM of Rock inhibitor (Abcam Biochemicals). One day after, EB were collected and cultured in rotation (60 rpm, orbital shaker) for 5 days in DMEM supplemented with 20% FBS, 1% NEAA, 1% Glutamine, 1% Pen/Strep and 0.1 mM β-mercaptoethanol. On D6, EBs were transferred to gelatin-coated plates and maintained in same medium for additional 19 days. Medium was changed every 2-3 days.
Immunocytochemistry
Following 4% PFA fixation for 10 min at RT, iPSC colonies or embryoid bodies were incubated 30 min at RT in blocking solution constituted by PBS containing 0.1% Triton X-100 and 3% BSA, to block nonspecific binding. Cells were then incubated 1 hour at RT, with the specific primary antibodies respectively (Table 2) , diluted in the blocking solution. Appropriate secondary antibodies were incubated for 45 min at RT. Nuclei were stained with DAPI. Images were captured with a LSM-700 (Zeiss) confocal microscope. Scale bar = 50 µm.
RNA extraction and RT-PCR
RNA was extracted by using RNeasy Mini kit (Qiagen) and reverse transcription was performed using the PrimeScript RT Reagent Kit (Takara) according to the manufacturer's instructions. PCR amplification was performed with a T3 Thermocycler PCR system (Biometra), by using Taq DNA Polymerase (Qiagen). The temperature cycling protocol was set as follows: initial degeneration step, 3 min at 95°C; followed by 35 cycles of denaturation: 30 s at 95°C; annealing: 30 s at 60°C; extension, 45 s at 72°C; final holding, 10 min at 72°C. Primers are listed in Table 2 .
Identification of MPS1 mutations
Genomic DNA was isolated from MPS1 fibroblasts and MPS1 iPSC by using the DNeasy® Blood & Tissue kit (Qiagen). Genotyping primers localized on intron 7 and exon 9 (Table 2) were used to amplify by PCR, the region of IDUA gene containing both mutations. PCR amplification was performed with a T3 Thermocycler PCR system (Biometra), by using Q5® High-Fidelity DNA Polymerase (New England Biolabs). The thermal cycling was performed as follows: initial degeneration step, 1 min at 95°C; 35 cycles (1 min at 95°C; 1 min at 58°C; 1 min at 72°C); and a final holding, 10 min at 72°C. PCR products were purified on 1% agarose gel before sequencing. To determine the allelic distribution of the 2 mutations further sequencing of TOPO cloned single PCR-fragments was performed.
CGH array
Oligonucleotide array-CGH was performed with the Human CGH Microarray Kit 4 × 44 K (Agilent Technologies). Data analysis was carried out with the Agilent Genomic Workbench software v6.5. Results Stem Cell Research 41 (2019) 101604 are given in GRCh37/hg19 genome version.
PCR-based mycoplasma test
20 000 cells were collected during passage. Cells have been lysed with 200 µg/ml of proteinase K in DirectPCR Lysis Reagent (Viagen Biotech) for 1 h at 56°C and 45 min at 85°C. Two PCR were performed from resulting lysate with specific primers of mycoplasma and ribosomal protein L32, listed in Table 2. 3.10. Short tandem repeat (STR) analysis PCR amplification of STR loci was achieved as described in Coble et al. (Coble M.D, Butler J.M. J Forensic Sci 2005). The allelic ladders were separated electrophoretically using size Standard GeneScan LIZ500 (Applied Biosystems). Sequencing was analyzed using Applied Biosystems 3730XL DNA Analyzer. with the following conditions: injection time, 10 s; injection voltage, 1.6 kV; run time, 2100s; run voltage, 15 kV; capillary length, 50 cm; polymer, POP7; filter, Dye Set G5. The primer sequence are listed in Table 2. 
